Britain and America have concluded a important commercial pact that will keep no duties on UK pharmaceutical shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to increase funding on drugs through the National Health Service (NHS). This pledge secures that tariffs on these crucial goods will be held at nothing for a timeframe of the next three years.
This development follows previous statements to hike import taxes on branded pharmaceutical products, with figures discussed as high as 100%.
"This arrangement between the Britain bolsters the worldwide climate for innovative medicines and establishes much-needed fairness to U.S.–U.K. medicine commerce," a release declared.
Trade Importance
Drugs represent one of the the United Kingdom's biggest export categories to the US, which is easily the largest buyer for major UK drugmakers.
Export figures indicate that in the year to the end of last September, the UK sold pharmaceutical products worth billions to the US. This value accounted for nearly one-fifth of all goods exports in that span.
"This agreement secures work, stimulates investment and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary stated.
Key NHS Changes
The deal involves several notable changes from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments topped 20%.
Industry Background
This agreement comes amid a ongoing row between the pharmaceutical industry and the UK government over medicine costs and approval rates.
The disagreement were heightened by assertions that US customers were charged several times more for the identical medicines than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official stated that the NHS must spend more on medicines, noting that its budget allocation on drugs had declined as a share of its total funding over the previous ten-year period.
